CD30 CAR-T / AbClon - LARVOL DELTA

AbClon Secures US Patent for CD30-Targeted CAR-T Technology (The Asia Business Daily) - "This patent covers a novel antibody that precisely targets the CD30 protein, which is distinctly overexpressed on the surface of cancer cells in patients with malignant lymphomas, including Hodgkin lymphoma, as well as next-generation CAR-T therapy technology applying this antibody. Since CD30 is expressed at extremely low levels in normal cells, targeting it enables an ideal treatment approach that powerfully and selectively destroys cancer cells while minimizing damage to normal cells."

Patent • Hodgkin Lymphoma

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer (ASH 2023) - P2a | "Our results demonstrated that BTLA KO significantly enhances the function of anti-CD30 CAR T cells in HVEM+ HL (Fig 1b), as assessed via tumor size (caliper) and CART30 expansion in the peripheral blood (flow cytometry)...Finally, we found that high BTLA RNA expression in tisagenlecleucel infusion products correlates with poor response to treatment in patients with DLBCL and FL (NCT02030834)... Our results reveal a critical role of the BTLA-HVEM axis in inhibiting CAR T cell function, and demonstrate that CRISPR-Cas9 deletion of BTLA leads to enhanced anti-tumor efficacy in multiple models of cancer. The key mechanism is the reduction of SHP-1/2 recruitment and the consequent increase in CAR T cell activation. The results of this study will be translated into a first in human clinical trial of BTLA-deficient CAR T cells for relapsed or refractory cancer."

CAR T-Cell Therapy • IO biomarker • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Melanoma • Oncology • Prostate Cancer • Solid Tumor • BTLA • HER-2 • IFNG • IL2 • PD-1 • TNFRSF14

AbClone announces CAR-T treatment for incurable cancer using gene scissors at ASH 2023 [Google translation] (HIT News) - "AbClon...jointly presented at the American Society of Hematology (ASH 2023) with the University of Pennsylvania School of Medicine about a new CAR-T (Carti) treatment that simultaneously targets the BTLA protein, which is the cause of immune resistance to cancer, and the cancer protein CD30. It was announced on the 12th that it was done...The new CARTI treatment showed excellent anti-cancer effects in tumor animal models, and the company confirmed that this effect was caused by the CARTI treatment with the BTLA protein removed suppressing the effects of regulatory T cells....AbClone jointly applied for a patent in the United States with the University of Pennsylvania and decided to expand joint research and development in the future."

Patent • Preclinical • Hematological Malignancies • Hodgkin Lymphoma • Oncology

Announcement of AT101 and new target CD30 CARTI treatment [Google translation] (Medipharms Today) - "AbClon...will participate in the 65th American Society of Hematology (ASH) to be held in San Diego, USA from December 9th to discuss its CAR-T treatment 'AT101' and its new target 'CD30' CARTI treatment. It was announced on the 13th that it would be jointly announced with the University of Pennsylvania School of Medicine in the United States...Additionally, AbClone is participating in ‘Bio Japan 2023’ currently being held in Japan....'We will strive for quick approval along with the successful progress of Phase 2 clinical trials for AT101.'"

New molecule • P1 data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology